GlassScriptPhysician profile
Frank J Lichtenberger
NPI 1750590097
$80,516.49
in general payments reported to CMS, 2019-2025
25 companies · $459 in 2025
The $459 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,011 · 2020: $2,147 · 2021: $3,168 · 2022: $4,505 · 2023: $29K · 2024: $34K · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Grant: $21K · Honoraria: $3,647 · Food and Beverage: $3,470 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,732 · Travel and Lodging: $1,250 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,082.63 |
| Grant | $21,375.00 |
| Honoraria | $3,647.00 |
| Food and Beverage | $3,469.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,731.50 |
| Travel and Lodging | $1,250.08 |
| Education | $128.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $35,350.02 | 2021-2025 | Ruconest, Joenja |
| Biocryst US Sales Co., LLC | $26,320.37 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $7,684.28 | 2020-2023 | Ayvakit |
| Genentech USA, INC. | $3,432.25 | 2019 | |
| Shire North American Group INC | $3,412.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,282.62 | 2020-2024 | Takhzyro, Cuvitru, Hyqvia |
| Biocryst Pharmaceuticals, INC. | $875.00 | 2020 | |
| Consortium of Independent Immunology Clinics, LLC | $400.00 | 2024 | |
| Tersera Therapeutics LLC | $295.73 | 2022-2024 | Quzyttir |
| Regeneron Healthcare Solutions, INC. | $257.47 | 2023-2025 | Dupixent |
| Csl Behring | $248.88 | 2023-2025 | Andembry, Haegarda |
| Genzyme Corporation | $211.93 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $155.89 | 2019-2025 | Tezspire, Fasenra |
| Novartis Pharmaceuticals Corporation | $86.07 | 2019 | |
| Pfizer INC. | $83.68 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $83.11 | 2023-2025 | Panzyga |
| Adma Biomanufacturing LLC | $82.63 | 2023 | |
| Ionis Pharmaceuticals, INC. | $48.77 | 2025 | Dawnzera |
| Alk-Abello, INC | $37.47 | 2019 | |
| Amgen INC. | $36.25 | 2023-2025 | Tezspire, Evenity |
| Optinose US, INC. | $33.91 | 2021-2024 | |
| Glaxosmithkline, LLC. | $31.38 | 2019-2023 | Trelegy Ellipta |
| Kedrion Biopharma, INC. | $24.19 | 2024 | Albuked, Koate, Rhogam Ultra-Filtered Plus |
| Avadel Cns Pharmaceuticals, LLC | $23.01 | 2024 | Lumryz |
| Abbvie INC. | $18.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$95,090.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Lichtenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.